Genmab A/S is a biotechnology business based in the US. Genmab A/S shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Genmab A/S employs 1,136 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Genmab A/S
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GMAB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Genmab A/S stock price (NASDAQ: GMAB)Use our graph to track the performance of GMAB stocks over time.
Genmab A/S shares at a glance
|Latest market close||$34.45|
|52-week range||$30.10 - $49.07|
|50-day moving average||$39.46|
|200-day moving average||$41.55|
|Wall St. target price||$46.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.67|
Buy Genmab A/S shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Genmab A/S stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Genmab A/S price performance over time
|1 week (2022-01-12)||-5.44%|
|1 month (2021-12-17)||-9.20%|
|3 months (2021-10-19)||-23.95%|
|6 months (2021-07-19)||-20.29%|
|1 year (2021-01-19)||-22.29%|
|2 years (2020-01-17)||51.43%|
|3 years (2019-01-18)||122.11%|
|5 years (2017-01-19)||90.05|
Is Genmab A/S stock undervalued or overvalued?
Valuing Genmab A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genmab A/S's P/E ratio
Genmab A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 53x. In other words, Genmab A/S shares trade at around 53x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Genmab A/S's PEG ratio
Genmab A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.6579. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Genmab A/S's EBITDA
Genmab A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.4 billion.
The EBITDA is a measure of a Genmab A/S's overall financial performance and is widely used to measure a its profitability.
Genmab A/S financials
|Revenue TTM||$7.9 billion|
|Operating margin TTM||39.43%|
|Gross profit TTM||$10.1 billion|
|Return on assets TTM||8.57%|
|Return on equity TTM||14.45%|
|Market capitalisation||$23.4 billion|
TTM: trailing 12 months
Genmab A/S share dividends
We're not expecting Genmab A/S to pay a dividend over the next 12 months.
Have Genmab A/S's shares ever split?
Genmab A/S's shares were split on a 5:1 basis on 30 April 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab A/S shares which in turn could have impacted Genmab A/S's share price.
Genmab A/S share price volatility
Over the last 12 months, Genmab A/S's shares have ranged in value from as little as $30.1 up to $49.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab A/S's is 0.6798. This would suggest that Genmab A/S's shares are less volatile than average (for this exchange).
Genmab A/S overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
Genmab A/S in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
RBC's Top 30 Global Stock Investments for 2022
Frequently asked questionsWhat percentage of Genmab A/S is owned by institutions?
Currently 7.186% of Genmab A/S shares are held by institutions. How many people work for Genmab A/S?
Latest data suggests 1,136 work at Genmab A/S. When does the fiscal year end for Genmab A/S?
Genmab A/S's fiscal year ends in December. Where is Genmab A/S based?
Genmab A/S's address is: Kalvebod Brygge 43, Copenhagen, Denmark, 1560 What is Genmab A/S's ISIN number?
Genmab A/S's international securities identification number is: US3723032062 What is Genmab A/S's CUSIP number?
Genmab A/S's Committee on Uniform Securities Identification Procedures number is: 372303206
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert